in vitro News and Research

RSS

Scientists detect emergence and spread of artemisinin-resistant malaria parasites in Rwanda

Resistance to artemisinin, the main component of the current antimalarial treatments recommended by WHO, is already widespread in South-East Asia, but it had not previously been described in Africa.

5 Aug 2020

De novo protein decoys that block SARS-CoV-2

Now, a new study published on the preprint server bioRxiv in August 2020 shows that computational design technology can be efficiently harnessed towards this end, producing new molecules to inhibit viral entry and replication.

5 Aug 2020

ACTG initiates novel clinical trial to evaluate multiple therapeutics for COVID-19

The AIDS Clinical Trials Group, the world's largest and longest established HIV research network, today announced the initiation of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the ACTG.

4 Aug 2020

Specifically designed cyclic peptide inhibitor shown to be active against SARS-CoV-2

A new bioRxiv study by a research group from the University of California Irvine shows in vitro activity and non-toxicity of the first-in-class cyclic peptide that inhibits the main protease of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – laying the groundwork for its use in the treatment of coronavirus disease (COVID-19).

4 Aug 2020

Regeneron antibody cocktail shows promise as potential COVID-19 treatment

Researchers in the U.S. have shown both preventive and treatment effects of an antibody cocktail in animal models of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Aug 2020

Study identifies possible therapeutic treatment for COVID-19

Yunjeong Kim and Kyeong-Ok "KC" Chang, virologists in the College of Veterinary Medicine at Kansas State University, have published a study showing a possible therapeutic treatment for COVID-19.

3 Aug 2020

Artificial intelligence can increase effectiveness of drug repurposing for psychiatric disorders

Artificial intelligence can increase the effectiveness of drug repositioning or repurposing research, according to a study published in Translational Psychiatry.

3 Aug 2020

SARS-CoV-2 lured away and trapped by a new decoy version of ACE2

Researchers in the United States and Canada have engineered affinity-optimized “receptor traps” that prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from binding to and infecting cells.

3 Aug 2020

Young women with polycystic ovary syndrome more likely to get heart disease

Women in their 30s and 40s with a common condition affecting how the ovaries work are more likely to get heart disease. That's the finding of a study published today in the European Journal of Preventive Cardiology, a journal of the European Society of Cardiology.

2 Aug 2020

Synthetic riboregulators detect SARS-CoV-2 genome parts in 40 minutes

By exploiting the tools of synthetic biology, the researchers from Turkey have successfully developed a de novo riboregulator system for rapidly detecting the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic material. Their paper is currently available on medRxiv preprint server.

2 Aug 2020

FDA authorizes first two COVID-19 serology tests

Today, the U.S. Food and Drug Administration authorized the first two COVID-19 serology tests that display an estimated quantity of antibodies present in the individual's blood.

1 Aug 2020

Konstanz biologists receive Ursula M. Händel Animal Welfare Prize

Marcel Leist, Professor of In-Vitro Toxicology and Biomedicine at the University of Konstanz, and Thomas Hartung, Professor of Environmental Health Sciences at the University of Konstanz and Doerenkamp-Zbinden Chair of Evidence-Based Toxicology at Johns Hopkins Bloomberg School of Public Health in Baltimore, have been awarded the Ursula M. Händel Animal Welfare Prize 2020 of the German Research Foundation.

31 Jul 2020

GlobalData: US medtech market expected to return to normal very quickly

Following the recent quarterly earnings reports for multiple American Medtech companies;

31 Jul 2020

New simple way of detecting COVID-19 in blood plasma

Even as the COVID-19 pandemic claims increasing numbers of patients, testing numbers are rising in most nations at the leading edge. However, the current reverse transcriptase-polymerase chain reaction (RT PCR) testing is often unavailable and takes up to several days for results to arrive.

31 Jul 2020

War of sugars - estrogen provides protection in COVID-19

Now a new study published on the preprint server bioRxiv in July 2020 reports that sex hormones could affect the function of the fusion protein that is dependent upon the human ACE2 receptor, thus preventing the entry of the virus into the host cell.

31 Jul 2020

Antimalarial drug shows in vitro activity against SARS-CoV-2 and flu viruses

Now, a new study published in the preprint server bioRxiv in July 2020 reports on the antiviral activity of two drugs found in an antimalarial drug currently in phase II trials in South Korea, called Pyramax.

30 Jul 2020

Study finds synthetic neutralizing/enhancing antibodies to SARS-CoV-2

A new study published on the preprint server bioRxiv in July 2020 reports the discovery of some antibody molecules that have powerful enhancing or neutralizing activity against the virus, in a library of synthetic antibodies. These hold the promise of being useful for the prevention or treatment of this illness.

30 Jul 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

Study explores if prior exposure to common cold viruses may affect SARS-CoV-2 severity

A study led by Charité - Universitätsmedizin Berlin and the Max Planck Institute for Molecular Genetics (MPIMG) shows that some healthy individuals possess immune cells capable of recognizing the novel coronavirus, SARS-CoV-2.

29 Jul 2020

COVID-19 test kits offered by Carolina Liquid Chemistries granted FDA emergency use authorization

Carolina Liquid Chemistries, Corp., an innovative leader in clinical diagnostics and drug screening, is now offering test kits for COVID-19 that have been granted Emergency Use Authorization by the US Food and Drug Administration, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act.

From Carolina Liquid Chemistries Corp. 29 Jul 2020